諾和諾德(NVO.US)口服版Wegovy在實驗中實現顯著減重效果
「減肥神藥」生產商、丹麥諾和諾德(Novo Nordisk)(NVO.US)在醫學雜誌上發表研究結果,指口服版Wegovy在後期實驗中實現顯著減重效果,與先前注射劑型的結果相符。
公司指,結果顯示,口服25毫克司美格魯(月太)(Semaglutide)的實驗群組在64星期內平均減重16.6%,而安慰劑組為2.7%;34.4%的服藥者減重達20%或以上,安慰劑組僅2.9%。
由於(月太)類藥物通常在到達血液前就會於腸道分解,開發口服劑型的司美格魯(月太)一直被認為是不可行,而諾和諾德嘗試通過添加促進胃部吸收的化合物以解決難題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.